These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
463 related items for PubMed ID: 15468045
1. Therapeutic goals in the treatment of Gaucher disease. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymańska A. Semin Hematol; 2004 Oct; 41(4 Suppl 5):4-14. PubMed ID: 15468045 [Abstract] [Full Text] [Related]
2. Individualization of long-term enzyme replacement therapy for Gaucher disease. Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, International Collaborative Gaucher Group U.S. Regional Coordinators. Genet Med; 2005 Feb; 7(2):105-10. PubMed ID: 15714077 [Abstract] [Full Text] [Related]
3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease]. Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM. Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655 [Abstract] [Full Text] [Related]
4. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone. Mikosch P. Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):665-81. PubMed ID: 22142746 [Abstract] [Full Text] [Related]
5. Clinically relevant therapeutic endpoints in type I Gaucher disease. Hollak CE, Maas M, Aerts JM. J Inherit Metab Dis; 2001 Oct; 24 Suppl 2():97-105; discussion 87-8. PubMed ID: 11758685 [Abstract] [Full Text] [Related]
6. Diagnosis and Management of Gaucher Disease in India - Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, Phadke SR, Sachdeva A, Verma IC, Mistry PK, Gaucher Disease Task Force. Indian Pediatr; 2018 Feb 15; 55(2):143-153. PubMed ID: 29503270 [Abstract] [Full Text] [Related]
7. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A. Eur J Pediatr; 2004 Feb 15; 163(2):58-66. PubMed ID: 14677061 [Abstract] [Full Text] [Related]
8. [Gaucher disease: A review]. Nguyen Y, Stirnemann J, Belmatoug N. Rev Med Interne; 2019 May 15; 40(5):313-322. PubMed ID: 30638965 [Abstract] [Full Text] [Related]
10. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM. Blood Cells Mol Dis; 2018 Feb 15; 68():203-208. PubMed ID: 28274788 [Abstract] [Full Text] [Related]
11. Gaucher disease: pediatric concerns. Elstein D, Abrahamov A, Dweck A, Hadas-Halpern I, Zimran A. Paediatr Drugs; 2002 Feb 15; 4(7):417-26. PubMed ID: 12083970 [Abstract] [Full Text] [Related]
12. The role of neurogenetics in Gaucher disease. Brady RO, Barton NW, Grabowski GA. Arch Neurol; 1993 Nov 15; 50(11):1212-24. PubMed ID: 8215980 [Abstract] [Full Text] [Related]
13. Gaucher Disease: Clinical, Biological and Therapeutic Aspects. Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Pathobiology; 2016 Nov 15; 83(1):13-23. PubMed ID: 26588331 [Abstract] [Full Text] [Related]
14. Therapeutic goals in Gaucher disease. Mistry P, Germain DP. Rev Med Interne; 2006 Mar 15; 27 Suppl 1():S30-8. PubMed ID: 16644400 [Abstract] [Full Text] [Related]
15. [Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000]. Niederau C, Rolfs A, vom Dahl S, Häussinger D, Poll LW, Mengel E, Beck M. Med Klin (Munich); 2001 Jan 15; 96(1):32-9. PubMed ID: 11210487 [Abstract] [Full Text] [Related]
16. Substrate reduction therapy of glycosphingolipid storage disorders. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. J Inherit Metab Dis; 2006 Jan 15; 29(2-3):449-56. PubMed ID: 16763917 [Abstract] [Full Text] [Related]
17. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Baldellou A, Andria G, Campbell PE, Charrow J, Cohen IJ, Grabowski GA, Harris CM, Kaplan P, McHugh K, Mengel E, Vellodi A. Eur J Pediatr; 2004 Feb 15; 163(2):67-75. PubMed ID: 14677062 [Abstract] [Full Text] [Related]
18. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report. Ceravolo F, Grisolia M, Sestito S, Falvo F, Moricca MT, Concolino D. J Med Case Rep; 2017 Jan 20; 11(1):19. PubMed ID: 28103924 [Abstract] [Full Text] [Related]
19. Pharmacological treatment of pediatric Gaucher disease. Gupta P, Pastores G. Expert Rev Clin Pharmacol; 2018 Dec 20; 11(12):1183-1194. PubMed ID: 30444430 [Abstract] [Full Text] [Related]
20. An overview on bone manifestations in Gaucher disease. Mikosch P, Hughes D. Wien Med Wochenschr; 2010 Dec 20; 160(23-24):609-24. PubMed ID: 21221913 [Abstract] [Full Text] [Related] Page: [Next] [New Search]